BACKGROUND: Probiotics are usually administered for the treatment of gastrointestinal and immune diseases, such as chronic inflammatory bowel diseases (IBD), intestinal bowel syndrome (IBS), and vaginal infections. This anecdotal spontaneous observational clinical study investigates the effcacy of a probiotic formulation composed by L. rhamnosus (LRH11), L. acidophilus (LA5) and B. lactis (BB12) enriched with short-chain fructose-oligosaccharides (FOS), in association with an individually tailored balanced diet and hydro-colon therapy, for the treatment of Crohn’s Disease, IBS,
diverticulitis, psoriasis and psoriatic arthritis.
METHODS: Forty-fve patients were enrolled at the second opinion Network, in Modena, Italy. Patients were administered 2 capsules/day for 3 months of the galenic formulation (1 capsule in the morning before having breakfast and 1 capsule in the evening before going to bed), and to follow a proper diet during the probiotic intake. Before starting the treatment and at the end of the study the concentration of faecal calprotectin (index of gut inflammation) was tested in order to assess intestinal inflammation by a quantitative rapid test points of care (POC) system and urinary indican and skatole concentration (for gut disbiosis), by colorimetric and liquid chromatography method, respectively. Furthermore, 7 patients affected by recent severe constipation and pain were submitted to one session of hydro colon-therapy to clean the gut, before starting the treatment.
RESULTS: after three months of treatment, urinary indican and faecal calprotectin values signifcantly decreased (P=0.005 and P=0.00 respectively), and clinical symptoms (evaluated by Scott-Huskisson scale) improved.
CONCLUSIONS: the association of our probiotic/prebiotic formulation with a balanced diet and hydro-colon therapy,
when required, was effective to improve inflammation and disbiosis in patients affected by Crohn’s Disease, IBS, diverticulitis, psoriasis and psoriatic arthritis, without side effects.
The aim of this paper was to investigate the main clinical effects of an original probiotic formulation based on Lactobacillus rhamnosus, Lactobacillus acidophilus LA5, and Bifdobacterium bifdum BB12 with short-chain fruit oligosaccharides. We searched Pubmed/Medline using the terms “Lactobacillus rhamnosus”, “Lactobacillus acidophilus”, “Bifd bacterium bifdum” and “short-chain fruit oligosaccharides”. Selected papers from 2000 to 2015 were chosen based on their content (evidence-based quality and reliability). In vivo experimental studies and clinical trials were considered. We did not fnd any scientifc report of a putative biological synergy among the three bacteria strains contemporarily administered. However, many evidences based on ex-vivo experimental studies, highlight the symptomatic advantages of each strain individual administration. The most suitable target of this mixed probiotic formulation is the gastrointestinal tract bacterial imbalance, diverticulitis, or Helicobacter pylory infections, and inflammatory bowel disease (IBD). Gut inflammation, and allergic diseases are improved by these strains modulating the Th1 lymphocyte population, rather than Th2, and a potential beneft in liver diseases, and lipid dismetabolism should be further deeply investigated.
Leggi Articolo- 1